胆前体胆酸治疗对轻度认知功能障碍的影响:一项随机对照试验
Anna Carotenuto1,2, Vincenzo Andreone2, Francesco Amenta1
1Telemedicine and Telepharmacy Centre, School of Medicinal and Health Products Sciences, University of Camerino, 62032 Camerino, Italy.
Medicina (Kaunas, Lithuania)
|June 27, 2024
概括
这项研究调查了胆酸是否可以减缓脑缩和认知衰退在轻度认知障碍 (MCI) 和血管损伤的成年人. 结果可能为MCI进展提供新的治疗方法.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 轻度认知障碍 (MCI) 增加了痴呆风险,并涉及大脑缩,特别是在海马体.
- 目前对MCI缺乏治疗方法,这凸显了有效干预措施的必要性.
- 血管损伤通常与认知能力下降和MCI进展有关.
研究的目的:
- 评估胆醇酸盐在稳定或减缓MCI和血管损伤患者的大脑缩的疗效.
- 评估胆醇酸盐对与MCI相关的认知和行为症状的影响.
- 探索胆固醇前体在治疗MCI中的潜在治疗益处.
主要方法:
- 一个为期12个月的随机对照试验,涉及60名患有MCI和血管损伤的患者.
- 参与者将被随机分配,接受1200毫克/天胆酸或安慰剂.
- 统计学意义将使用SPSS版本26确定,p值为0.05.
主要成果:
- 该部分是在研究完成后填写的.
结论:
- 这项试验可能为胆酸在治疗MCI的疗效提供证据.
- 这些发现可以为未来的治疗策略提供信息,以预防认知功能障碍和痴呆症.
- 结果将在同行评审期刊上发表,以促进科学知识.
更多相关视频
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
2.9K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.3K
相关概念视频
Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
118
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
118
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
